The availability of 3D structural information plays a vital role in modern drug discovery programs. At ZoBio we deeply understand this and have invested heavily in building a team and a lab to create a powerful X-ray crystallography workflow specifically …
Contributing All the Way to the Clinic
Recently the ZoBio team made an important contribution to a drug discovery project for our client Mirati Therapeutics that we are particularly proud of and has had significant impact [1]. This work describes a program to develop inhibitors of the epigenetic target PRMT5 with the potential to …
Eurostars DiscoveRNA Project Awarded!
RNA as a potential drug target is currently gaining a lot of interest, but the right technologies are not all in place to successfully pursue them. ZoBio and its partner ETH Zurich have been awarded with a €1.2 million EUREKA Eurostars grant, to establish an automated pipeline enabling…
Remarkable NMR Achievement in Collaboration with ESSA Pharma
The androgen receptor (AR) pathway drives most metastatic, castration-resistant prostate cancers (mCRPC). Anti-androgen resistance mechanisms include AR gene amplification, C-terminal ligand-binding domain (LBD) mutations and expression of constitutively-active truncated AR splice variants lacking…